Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study (Q40295439)

19 September 2017

Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study (English)

1 reference

19 September 2017

0 references

1 reference

1

Hagop Kantarjian

1 reference

19 September 2017

10

Stefan Faderl

1 reference

19 September 2017

12

Jorge Cortes

1 reference

19 September 2017

18

Susan O'Brien

1 reference

19 September 2017

8

Farhad Ravandi

1 reference

19 September 2017

4

Elias Jabbour

1 reference

19 September 2017

11

Mary Beth Rios

1 reference

19 September 2017

13

Luis Fayad

1 reference

19 September 2017

3

Jeffrey Jorgensen

1 reference

19 September 2017

16

Richard Champlin

1 reference

19 September 2017

5

Partow Kebriaei

1 reference

19 September 2017

6

Michael Rytting

1 reference

19 September 2017

9

Monica Kwari

1 reference

19 September 2017

7

Sergernne York

1 reference

19 September 2017

17

Anjali Advani

1 reference

19 September 2017

Deborah Thomas

2

1 reference

PubMed ID

22357140

19 September 2017

Robert Tarnai

series ordinal

14

1 reference

PubMed ID

22357140

19 September 2017

Sa A Wang

series ordinal

15

1 reference

19 September 2017

21 February 2012

1 reference

Lancet Oncology Commission

19 September 2017

1 reference

19 September 2017

13

1 reference

19 September 2017

403-411

1 reference

19 September 2017

4

1 reference

Treatment of acute lymphoblastic leukemia

19 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970386-2

7 January 2021

Biology, risk stratification, and therapy of pediatric acute leukemias: an update

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970386-2

7 January 2021

Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983-1995.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970386-2

7 January 2021

Treatment of Adult ALL according to protocols of the German Multicenter Study Group for Adult ALL (GMALL).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970386-2

7 January 2021

Modern therapy of acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970386-2

7 January 2021

Adult acute lymphoblastic leukemia: concepts and strategies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970386-2

7 January 2021

Treatment of adult acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970386-2

7 January 2021

Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970386-2

7 January 2021

Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970386-2

7 January 2021

Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970386-2

7 January 2021

Treating childhood acute lymphoblastic leukemia without cranial irradiation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970386-2

7 January 2021

Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970386-2

7 January 2021

First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970386-2

7 January 2021

Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970386-2

7 January 2021

Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970386-2

7 January 2021

Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970386-2

7 January 2021

Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970386-2

7 January 2021

Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970386-2

7 January 2021

Surface antigens analysis reveals significant expression of candidate targets for immunotherapy in adult acute lymphoid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970386-2

7 January 2021

Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970386-2

7 January 2021

Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970386-2

7 January 2021

Understanding and exploiting nature's chemical arsenal: the past, present and future of calicheamicin research.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970386-2

7 January 2021

Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970386-2

7 January 2021

Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970386-2

7 January 2021

Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970386-2

7 January 2021

Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970386-2

7 January 2021

10.1016/S1470-2045(11)70386-2

Identifiers

DOI

1 reference

19 September 2017

1 reference

PubMed ID

22357140